Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Additionally, we evaluated the expression of GLS1 in calcified arteries from mice administered with AP diet or subjected to Vitamin‐D3 (VitD3) injection.[ 28a,b,c ] Immunofluorescence staining and immunohistochemical staining from mice also showed the increased expression of GLS1 in calcified aortic (Figure 1L,M).
Source: GLS1 and Its Catalyzed Production Glutamate Are Positively Associated with Arterial Calcification. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
GLS1‐Mediated Redundancy in Glutamate Accelerates Arterial Calcification via Activating NMDAR/Ca2+/β‐Catenin Pathway
Study design awaiting verification · Advanced Science · 2025
Original publication title
GLS1‐Mediated Redundancy in Glutamate Accelerates Arterial Calcification via Activating NMDAR/Ca2+/β‐Catenin Pathway
© 2025 The Author(s). Advanced Science published by Wiley‐VCH GmbH
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Abstract
Arterial calcification is a powerful predictor of both the events and mortality associated with cardiovascular diseases in chronic kidney disease (CKD) patients. GLS1 (glutaminase 1), a rate‐limiting enzyme catalyzing the conversion of glutamine to glutamate, is disordered in various cardiovascular diseases. However, the potential interplay between GLS1‐mediated glutamate production and arterial calcification remains poorly understood. Here, LC‐MS/MS analysis of CKD patients’ samples shows an abnormally elevated activity of GLS1, reflected by the increased glutamate/glutamine ratio. Moreover, GLS1 activity is positively correlated with arterial calcification progression, and its expression is upregulated in calcified arteries.
Treatment with GLS1 inhibitors or knockdown of GLS1 alleviates osteogenic reprogramming. In contrast, glutamate administration boosts the development of arterial calcification. Mechanistically, GLS1 redundancy‐regulated glutamate superfluity stimulates the activation of N‐methyl‐d‐aspartate receptors (NMDAR), leading to Ca2+ influx and extracellular regulated protein kinases (ERK) phosphorylation, followed by the nuclear translocation of β‐Catenin and acceleration of osteogenic reprogramming of vascular smooth muscle cells (VSMCs) in further. This research defines GLS1 as a key contributor to arterial calcification. Glutamate, a major product of GLS1‐mediated glutamine metabolism, exerts a deleterious effect on arterial calcification by activating NMDAR and subsequently triggering Ca2+ influx, which in turn exacerbates β‐Catenin‐regulated osteogenic reprogramming in VSMCs.
Authors’ abstract
Abstract
Arterial calcification is a powerful predictor of both the events and mortality associated with cardiovascular diseases in chronic kidney disease (CKD) patients. GLS1 (glutaminase 1), a rate‐limiting enzyme catalyzing the conversion of glutamine to glutamate, is disordered in various cardiovascular diseases. However, the potential interplay between GLS1‐mediated glutamate production and arterial calcification remains poorly understood. Here, LC‐MS/MS analysis of CKD patients’ samples shows an abnormally elevated activity of GLS1, reflected by the increased glutamate/glutamine ratio. Moreover, GLS1 activity is positively correlated with arterial calcification progression, and its expression is upregulated in calcified arteries.
Treatment with GLS1 inhibitors or knockdown of GLS1 alleviates osteogenic reprogramming. In contrast, glutamate administration boosts the development of arterial calcification. Mechanistically, GLS1 redundancy‐regulated glutamate superfluity stimulates the activation of N‐methyl‐d‐aspartate receptors (NMDAR), leading to Ca2+ influx and extracellular regulated protein kinases (ERK) phosphorylation, followed by the nuclear translocation of β‐Catenin and acceleration of osteogenic reprogramming of vascular smooth muscle cells (VSMCs) in further. This research defines GLS1 as a key contributor to arterial calcification. Glutamate, a major product of GLS1‐mediated glutamine metabolism, exerts a deleterious effect on arterial calcification by activating NMDAR and subsequently triggering Ca2+ influx, which in turn exacerbates β‐Catenin‐regulated osteogenic reprogramming in VSMCs.
Publication and source details
Original title: GLS1‐Mediated Redundancy in Glutamate Accelerates Arterial Calcification via Activating NMDAR/Ca2+/β‐Catenin Pathway
Ziting Zhou; Bing Dong; Dayu He; Jianshuai Ma; Yun Kong; Huijin Zhu; Chen Xie; Tiecheng Yang; Xin Zhen; Zhengzhipeng Zhang; Zhaohui He; Jinkun Cheng; Aoran Huang; Jie Chen; Ruo Wu; Huiyong Yin; Yanlian Chen; Jun Tao; Hui Huang
Advanced Science · 2025
* E‐mail: hyyin@sibs.ac.cn; chenylian3@mail.sysu.edu.cn; taojun@mail.sysu.edu.cn; huangh8@mail.sysu.edu.cn© 2025 The Author(s). Advanced Science published by Wiley‐VCH GmbHhttps://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.Shenzhen Medical Research FundB2302020D2401025A2302015A2302013Key Areas Research and Development Program of Guangzhou202206080004Shenzhen Science and Technology Program Shenzhen Science and Technology Innovation ProgramKCXFZ20211020163801002ZDSYS20220606100801004SGDX20230116092459009Shenzhen Key Medical Discipline Construction FundSZXK002Shenzhen Science and Technology Innovation Program 10.13039/501100017610JCYJ20220530144214032JCYJ20220530144211025JCYJ20240813150714019Futian District Public Health Scientific Research Project of ShenzhenFTWS2022001FTWS2022004FTWS2023055FTWS2022067FTWS2023062Chinese Association of Integrative Medicine‐Shanghai Hutchison Pharmaceuticals FundHMPE202202China Heart House‐Chinese Cardiovascular Association HX fund2022‐CCA‐HX‐090Postdoctoral Researcher Program of China2024M753761GZC20233254RGC Theme‐based Research Scheme8770011Startup Funds from the City University of Hong Kong9380154TBSC Project FundBasic and Applied Basic Research Foundation of Guangdong Province 10.13039/5011000211712023A15150102732022A15152201922024A15150129652023A1515111024National Natural Science Foundation of China 10.13039/501100001809823B20088233002182400860822707718210165982471583824B20163203005382073408
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T05:30:59.006937+00:00
DOI: 10.1002/advs.202414252 · PMC12140355